Enrico Barichello

Webinar: Breaking the Concentration Barrier: New Long - Term Stability and PK Data for Subcutaneous Nanotrastuzumab High-dose biologics can make SubQ delivery challenging due to viscosity, stability, and injection volume limitations. Discover how Nanoform’s nanoparticle engineering technology enabled an ultra-high concentration trastuzumab suspension at 440 mg/mL, delivering 75% lower injection volume and promising stability and pharmacokinetic performance.

Crystal Salvans and Enrico Barichello provide an in-depth look at the evolving landscape of subcutaneous drug delivery, focusing on the increasing demand for patient-friendly solutions that accommodate high-viscosity biologics. Central to the discussion is Aptar Pharma’s 8 mm Rigid Needle Shield (RNS). Aptar Pharma’s 8 mm RNS is designed by leveraging decades of expertise in RNS technology, a market-proven rubber formulation, and a state-of-the-art manufacturing process.

Citation: Barichello E, Sutton C N, “Proving the Design Space: Advancing the Development of Syringe-Device Combinations”. ONdrugDelivery, Issue 178 (Oct 2025), pp 10–15.